Global Information
회사소개 | 문의 | 비교리스트

녹농균성 폐렴 : 파이프라인 리뷰

Pseudomonas aeruginosa Pneumonia (Infectious Disease) - Drugs In Development, 2021

리서치사 Global Markets Direct
발행일 2021년 07월 상품코드 484628
페이지 정보 영문 36 Pages 배송안내
가격
US $ 2,000 ₩ 2,841,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,682,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 8,523,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


녹농균성 폐렴 : 파이프라인 리뷰 Pseudomonas aeruginosa Pneumonia (Infectious Disease) - Drugs In Development, 2021
발행일 : 2021년 07월 페이지 정보 : 영문 36 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

녹농균은 폐렴이 중요한 원인이며 1주간 이상 입원한 환자에게서 나오는 가장 일반적인 병원체입니다. 증후는 열, 피로, 가려운 발진, 출혈성 궤양과 두통 등입니다. 위험인자는 연령과 면역력 저하 등입니다. 치료에는 항생물질을 사용합니다.

세계 각국에서의 녹농균성 폐렴(Pseudomonas aeruginosa Pneumonia) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

녹농균성 폐렴 : 개요

녹농균성 폐렴 : 치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 : 기업별
  • 파이프라인 제품 : 대학/연구기관별
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Aridis Pharmaceuticals LLC
  • Emergent BioSolutions Inc
  • MedImmune LLC
  • Polyphor Ltd

약제 프로파일

휴지 상태인 프로젝트

부록

도표

LSH 17.06.21

List of Tables

List of Tables

  • Number of Products under Development for Pseudomonas aeruginosa Pneumonia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Aridis Pharmaceuticals Inc, 2021
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Armata Pharmaceuticals, 2021
  • Pseudomonas aeruginosa Pneumonia - Pipeline by AstraZeneca Plc, 2021
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Ayuvis Research Inc, 2021
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Pedanius Therapeutics Ltd, 2021
  • Pseudomonas aeruginosa Pneumonia - Dormant Projects, 2021
  • Pseudomonas aeruginosa Pneumonia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Pseudomonas aeruginosa Pneumonia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Pneumonia - Drugs In Development, 2021, provides an overview of the Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of pneumonia. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Pneumonia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Pseudomonas aeruginosa Pneumonia - Overview
  • Pseudomonas aeruginosa Pneumonia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Pseudomonas aeruginosa Pneumonia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pseudomonas aeruginosa Pneumonia - Companies Involved in Therapeutics Development
  • Aridis Pharmaceuticals Inc
  • Armata Pharmaceuticals
  • AstraZeneca Plc
  • Ayuvis Research Inc
  • Pedanius Therapeutics Ltd
  • Pseudomonas aeruginosa Pneumonia - Drug Profiles
  • APPA-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVR-86 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Pseudomonas aeruginosa Pneumonia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • panobacumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PED-014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PED-015 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PED-019 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pseudomonas aeruginosa Pneumonia - Dormant Projects
  • Pseudomonas aeruginosa Pneumonia - Discontinued Products
  • Pseudomonas aeruginosa Pneumonia - Product Development Milestones
  • Featured News & Press Releases
  • Sep 26, 2017: Study Investigates Novel Immunotherapeutic Delivery Strategy for Preventing Infection with Antibiotic Resistant Bacteria
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q